<SEC-DOCUMENT>0001628280-17-007773.txt : 20170801
<SEC-HEADER>0001628280-17-007773.hdr.sgml : 20170801
<ACCEPTANCE-DATETIME>20170801165922
ACCESSION NUMBER:		0001628280-17-007773
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170801
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20170801
DATE AS OF CHANGE:		20170801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		17997380

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k-totectusshipments.htm
<DESCRIPTION>8-K - TOTECT US SHIPMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s68e494eda5a74f18908a555dbdfc85a6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):                &#160;                       August 1, 2017 (July 31, 2017)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  (615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 31, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the Company began distributing dexrazoxane, sold under the brand name Totect</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, to U.S. wholesalers.  Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation.  Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures and enable patients to continue their essential anti-cancer treatment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:61%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 1, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated July 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease-totectdistrib.htm
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE - TOTECT DISTRIBUTION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1dca6c64f6a34c8f963762cdccbfb993"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="cumberlanda06.gif" alt="cumberlanda06.gif" style="font-size:11pt;height:92px;width:401px;"></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS BEGIN U.S. SHIPMENTS </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OF DEXRAZOXANE FOR ONCOLOGY PATIENT SUPPORT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tenn., July 31, 2017 - Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)</font><font style="font-family:inherit;font-size:12pt;">, a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing dexrazoxane, sold under the brand name Totect</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, to U.S. wholesalers today. Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures and enable patients to continue their essential anti-cancer treatment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are delighted to make Totect (dexrazoxane) available for oncology patients throughout the U.S.,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We look forward to continuing to expand our activities into oncology while working to deliver products that improve the quality of care for patients.&#8221; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect is Cumberland&#8217;s second oncology support product and complements its current portfolio of specialty pharmaceuticals. It is also the second product Clinigen has licensed to Cumberland under the Strategic Alliance the two companies signed. Under the terms of the agreement, Cumberland is managing all marketing, promotion, and distribution of Totect</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></font><font style="font-family:inherit;font-size:12pt;">in the U.S. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Totect</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(dexrazoxane)</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect is an anthracycline extravasation agent approved by the United States Food and Drug Administration. Anthracyclines are used to treat many types of cancer and are among the most common cancer therapies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Anthracycline extravasation occurs when there is accidental leaking of the intravenously-administered medication into the surrounding tissues.  Anthracycline extravasation can result in serious complications for cancer patients including tissue necrosis with skin ulceration. In addition to tissue damage, an anthracycline extravasation may cause damage to the nerves, tendons, muscle, and joints. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information please visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.totect.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product portfolio with a focus in the areas of hospital acute care and gastroenterology. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(lactulose) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(conivaptan) Injection, for the treatment of hyponatremia, Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of H. pylori and duodenal ulcer disease, and Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(amifostine) for Injection, for the prevention of treatment-related adverse reactions in oncology patients.  Cumberland is also dedicated to developing innovative products that address unmet medical needs. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company&#8217;s product candidates in clinical development include: Hepatoren</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ifetroban) Injection for the treatment of hepatorenal syndrome, Boxaban</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ifetroban) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, Vasculan&#8482; (ifetroban) Oral Capsule for the treatment of systemic sclerosis and Portaban&#8482; (ifetroban) Oral Capsule for the treatment of portal hypertension. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland Pharmaceuticals Inc., please visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.cumberlandpharma.com.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investor Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;Media Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Supply Contact:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Erin Smith</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;Rebecca Kirkham</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Jim Herman</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Corporate Relations</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;Lovell Communications</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(615) 255-0068</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;(615) 297-7766</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(615) 255-0068</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlanda06.gif
<TEXT>
begin 644 cumberlanda06.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
M B@80>7Y,02 ",$#<)FYYYF8&H9$\11Z(0[D.="+J=Q7=;0R(L6YQ+_2M-@H
M25)CB-DX7SV^W7(W2.$$IV3!-)VQD'R\LY*LE6!4A:J1)AG'_M$W?Q;6SBY-
M3,&L$E&0+-TJ!![@1T#T8VL^T <'ULR!'[3Y_P<'\ $9&-1!JISNRM<#A)X9
M$<0^\[G/ NP8B$/@7SD.VI6J K%5K.4D^DX(Q'P&#:#Y3&D_6_HD(8;TGBU=
M:3Z#6%5ZMO2D+VTN.U^% "'V"GT9AT/# F#043Z@6N3!"$*?#R2']B*Y0OUG
M3O<YFJ5&X1T?[!$', #%UVW>%%"!V7=N !#028D/?J" 'UC;VFO6AYI_( X(
MY"S:N%4AA:F! ""8^]SH3C<5($#"*9S"W*4I+0DA@(!WG_5)[C8WNUE""@.8
M^P$DH8*_TTWP<QL  0<08 '>7?"& \$/!Q#) 1CN<(,C@ H UQ<CQ@"$4U!!
ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
MHAP;7HD6/Q4$0)G]X"WRD/\  4#@0$ #"0P$((^ / " Y#'LQ_#A080 &"$\
M2$"C0(H .GH$T.\C( (.*X)LN#!A0I42/3(\61 AR882):ITJ#$CQ9$?*_H$
M29.CP((163+,Z=*H09+R9)ZT")4CPQ "+W+4.=2@5)TPGP;5^/!H2JDH*7X]
MV?%?60@^?$Q!=4"<@@,^R*#EV,^C7JA @7+5BI OPJME#1LN_/?P8<50\2+>
MNEARP\F3@?]>)#!8H&:,E3V;1=DY=.3&5@5++OS9LE[,G-=2!JD74"H?J%)-
MZ75 @00.=%-M2!TS<$C'FP_VN\IYZ-72!(>K3@N=^&:HA8.;!KVX^4F&VSV+
MI,YX*,_GURT_ER[9+W;OTL]B-SSXM50R4VJ+DZM _P\.I*9Q^.$ VNYB9#N9
MOE(LL[S**LJYT:#22SFIF$LONZ@>) H]P#*L3$*0*-2PK(] 5/"S$B-3;S)&
M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
